/PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced the.
/PRNewswire/ Interim data from Phase I/II trials of RGX-121 for the treatment of MPS II and RGX-111 for the treatment of MPS I to be presented REGENXBIO Inc..
Objective Acuity announces successful pilot study in children with CLN2 Batten disease
News provided by
Share this article
AUCKLAND, New Zealand, May 10, 2021 /PRNewswire/
Objective Acuity ( OAL ) today announced the completion of a pilot study using OAL s threshold visual acuity test for young children diagnosed with late-infantile neuronal ceroid lipofuscinosis Type 2 (CLN2 disease), a form of Batten disease.
A prominent feature of CLN2 disease is vision loss, which typically develops when cognitive, motor and language impairments are already present. Measurement of visual acuity of those with the disease using standard methods is difficult and unreliable due to the age of those affected and their cognitive, language, and motor impairments.